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Cytotoxic T lymphocytes (CTL) capable of recognizing prototype hepatitis C virus (HCV) sequences have been shown to
localize to the liver in chronically infected individuals, where they are thought to influence hepatic inflammation and viral
replication. We isolated three intrahepatic CD81 CTL clones from two individuals with chronic HCV infection and compared
the recognition of prototype and autologous HCV sequences. These CTL recognized epitopes within the NS2 (amino acids
957–964) or NS3 (amino acids 1402–1410 and 1406–1415) proteins in the context of HLA B37, B8, or A2.1, respectively. The
corresponding predominant autologous HCV sequences (SDWAANGL, ELAAKLVGL, and ALRGMGVNAV, respectively) dif-
fered from the HCV-1 sequences used for screening (RDWAHNGL, ELAAKLVAL, and KLVALGINAV, respectively) at one to five
residues. For each CTL clone, recognition of the autologous HCV sequence required significantly higher peptide concen-
trations than did recognition of the HCV-1 sequence; for two of the clones, recognition was minimal or absent at peptide
concentrations as high as 25 mM. These data show that intrahepatic HCV-specific CD81 CTL clones can be relatively
inefficient at recognizing autologous viral epitopes. Inefficient recognition of autologous HCV sequences should influence the
interpretation of data generated using prototype HCV sequences and might have implications in vivo. © 1998 Academic Press
INTRODUCTION
Hepatitis C virus (HCV) is the major cause of non-A,
non-B viral hepatitis in the United States (Choo et al.,
1989). With a worldwide seroprevalence rate of 0.5–4%,
HCV infections are an important health problem because
$85% of patients become chronically infected and many
develop chronic hepatitis (Alter, 1995; Rall and Dienstag,
1995). The pathogenesis of chronic HCV infections is
poorly understood. Initially it was believed that liver dam-
age was caused primarily by viral cytopathic effects, but
recent data suggest that the immune response to HCV
infection plays a major role in causing liver injury
(Gonzalez-Peralta and Lau, 1995; Nelson et al., 1997;
Walker, 1996). In addition, it has been shown that HCV-
specific CTL activity is more commonly found in the liver
than in the peripheral circulation and that patients with
intrahepatic HCV-specific CTL activity had lower levels of
viremia with those with more active liver disease (Nelson
et al., 1997). These observations suggest that tissue-
specific localization of antiviral CTL plays an important
role in liver injury in chronic HCV infections. Because
HCV is known to be highly variable in sequence, the
detailed characterization of the interaction of individual
HCV-specific CTL clones with autologous viral se-
quences might be important for understanding the mech-
anisms by which HCV is able to establish a chronic
infection.
In this report, we describe the isolation and charac-
terization of three intrahepatic HCV-specific CTL clones
isolated from two individuals with chronic HCV infection.
We determined the autologous sequence of each CTL
epitope from endogenous plasma viral RNA in each
patient. All three clones recognized the autologous viral
epitope significantly less efficiently than prototype HCV
sequences.
RESULTS
Isolation of HCV-specific intrahepatic CTL
We expanded T lymphocytes from liver biopsy samples
of two subjects with chronic hepatitis C infection. Lympho-
cytes from patient HCV58 expanded in bulk culture after
initially culturing with recombinant human interleukin-2
(rhIL-2) alone lysed autologous B lymphoblastoid cell lines
(B-LCLs) infected with the recombinant vaccinia virus vvE2-
NS3 but not cells infected with vvC-NS2, demonstrating that
this T cell line recognized the HCV NS3 protein (Data not
shown). This bulk culture was subcloned by limiting dilu-
tion, and a clone, HCV58A1.4, was isolated that recognized
the NS3 region of HCV (Fig. 1A).
Lymphocytes from the liver tissue of patient HCV57
were grown in limiting dilution. Of the 39 wells expanded
from limiting dilution, five (13%) preferentially lysed au-
tologous B-LCLs infected with one or more of the HCV-
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expressing vaccinia constructs (Fig. 1B and data not
shown). Clone HCV57.19 was specific for an epitope
within the NS3 region of HCV because it lysed only target
cells that were infected with the vaccinia construct ex-
pressing the E2-NS3 region of HCV. Clone HCV57.8 rec-
ognized target cells infected with either the vvC-NS2 or
vvE2-NS3 and therefore was specific for an epitope
within the E2-NS2 region (Fig. 1B). Immunofluorescent
staining showed that all three CTL clones were CD42
CD81 (Data not shown).
HLA restriction analysis of CTL clones
To determine the HLA class I restriction of recognition
by these three clones, we analyzed their ability to lyse
allogeneic B-LCLs expressing HCV proteins. Clone
HCV57.8 recognized allogeneic target cells infected with
vvE2-NS3 when the target cells shared the HLA B37
allele but did not lyse infected targets that lacked B37 but
shared any other class I allele (Fig. 2A). Clone HCV57.19
lysed only HCV NS3-expressing allogeneic target cells
that also expressed HLA-A2 (data not shown). To confirm
that the clone was restricted by HLA A2.1, a chromium
release assay was performed using HmyCr1 cells or
transfected HmyCr1 cells expressing HLA A2.1 as tar-
gets. HmyCr1 cells do not express MHC class I mole-
cules on their surface. HCV57.19 recognized only HLA-
A2.1 transfected HmyCr1 cells expressing the HCV NS3
protein and did not recognize untransfected HmyCr1
cells (Fig. 2B).
Clone HCV58A1.4 recognized allogeneic target cells
expressing the HCV NS3 protein when the target cells
shared HLA-B8 but failed to recognize targets that
shared other HLA class I alleles (Fig. 2C). These data
show that HCV57.19 was HLA-A2.1 restricted, HCV57.8
was HLA-B37 restricted, and HCV58A1.4 was HLA-B8
restricted.
Epitope mapping of CTL clones
We then defined the epitopes recognized by the HCV-
specific CTL clones. To determine the epitope recog-
nized by HCV57.19, a panel of 26 peptides, nine or 10
amino acids in length, within the NS3 region of HCV were
examined for their ability to sensitize autologous B-LCL
FIG. 2. HLA restriction of recognition by clones HCV57.19 and
HCV58A1.4. Target cells were infected with recombinant vaccinia virus
vvE2-NS3 (black bars) or control vaccinia virus (open bars). (A) Clone
HCV57.8 (HLA A2, A3, B7, B37, Cw6, Cw7) was tested for recognition of
allogenic B-LCL at an E/T ratio of 10:1. (B) Clone HCV57.19 was tested
for recognition of autologous B-LCL, HmyCR1 cells transfected with the
HLA-A2.1 gene, or untransfected HmyCR1 cells at an E/T ratio of 10:1.
(C) Clone HCV58A1.4 from patient HCV58 (HLA A2, A3, B7, B8, Cw7)
was tested for recognition of allogeneic B-LCL at an E/T ratio of 20:1.
FIG. 1. HCV-specific CTL activity of intrahepatic lymphocytes. CTL
activity was determined using autologous B-LCLs as target cells in
chromium release assays. Target cells were infected with vvC-NS2
(black bars), vvE2-NS3 (gray bars), or control vaccinia virus (open bars).
(A) HCV58A1.4, a subclone of line HCV58A from patient HCV58, was
tested at an E/T ratio of 20:1. (B) HCV57.19 and HCV57.8, T cell lines from
patient HCV57, were tested at an E/T ratios of 10:1.
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targets for lysis. These peptides, provided by Dr. Francis
Chisari of the Scripps Research Institute, were identified
as potential HLA-A2.1-restricted CTL epitopes based on
the presence of the HLA-A2.1 binding motif (Falk et al.,
1991). HCV57.19 recognized only target cells loaded with
the peptide 1406–1415 (KLVALGINAV) (Fig. 3). Analysis
using N- or C-terminal truncations of this peptide
showed that the 10-mer was the optimal peptide for CTL
recognition (data not shown).
The region recognized by clone HCV57.8 was lo-
cated between amino acids 826 and 970; in addition to
recognizing the vvC-NS2 and vvE2-NS3 constructs, the
clone could recognize target cells infected with a
recombinant vaccinia virus expressing amino acids
826–3011 of HCV (data not shown). We identified the
optimal epitope for recognition by screening a panel of
overlapping peptides 20 amino acids in length. The
clone was able to lyse autologous B-LCL target cells
loaded with the peptide 951–970 (NHLTPLRDWAHN-
GLRDLAVA) (data not shown). The N- and C-terminal
truncations of this peptide were tested, and the opti-
mal peptide recognized by the clone was the peptide
957–964 (RDWAHNGL) (Table 1).
The region that contained the epitope recognized by
HCV58A1.4 was identified by screening a series of over-
lapping peptides 20 amino acids in length corresponding
to the HCV NS3 protein. The clone was able to lyse target
cells loaded with two overlapping 20-mers; 1391–1410
and 1401–1420 (Table 2). Subsequent N- and C-terminal
truncations were synthesized, and the nonamer 1402–
1410 (ELAAKLVAL) was identified as the smallest peptide
recognized by the clone (Table 2).
Genotype of endogenous plasma viral RNA and
sequence of autologous CTL epitopes in each patient
Because there are at least seven different genotypes
of HCV, we were interested in determining the genotype
of the viruses in each of these patients. The genotypes of
the viral RNA in the plasmas of patients HCV57 and
HCV58 were determined by using the second-generation
RT-PCR method of genotyping HCV. After PCR analysis
on plasma viral RNA for each patient, it was determined
that patient HCV57 was infected with a virus of genotype
2a and patient HCV58 was infected with a virus of ge-
notype 1a (data not shown). We sequenced the CTL
epitopes from autologous virus in each patient by ampli-
fying the region in the genome containing each epitope,
cloning the PCR product, and transforming bacteria with
the plasmid containing the insert. The majority of trans-
formants for the sequence of the epitope recognized by
HCV57.8 (RDWAHNGL) were found to be identical to the
HCV-J6 (genotype 2a) sequence (SDWAANGL; GenBank
accession number D00944), whereas variant sequences
were detected (Fig. 4A). The autologous viral sequence
for the epitope recognized by HCV57.19 (KLVALGINAV)
was also found to be identical to the HCV-J6 sequence
(ALRGMGVNAV) as 10 of 10 transformants contained this
FIG. 3. Mapping of the CTL epitope recognized by CTL clone
HCV57.19. HCV NS3-derived peptides containing the HLA-A2.1 binding
motif were loaded onto autologous B-LCLs at a concentration of 10
mg/ml, and the cells were used as targets in a 6-h chromium release
assay. Effector cells were added at an E/T ratio of 10:1.
TABLE 1
Mapping of the Epitope Recognized by the HLA-B37 Restricted HCV-Specific CTL Clone HCV57.8
Experiment Peptide
Lysis (%)
25 mM 250 nM 2.5 nM No peptide
1 951–970 NHLTPLRDWAHNGLRDLAVA 75 10
954–967 TPLRDWAHNGLRDL 60 10
957–970 RDWAHNGLRDLAVA 74 10
951–964 NHLTPLRDWAHNGL 83 10
957–965 RDWAHNGLR 83 10
957–964 RDWAHNGL 72 10
2 957–965 RDWAHNGLR 66 4 6
957–964 RDWAHNGL 68 53 6
Note. HCV NS2-derived peptides were loaded onto autologous B-LCLs and used as target cells in 6-h chromium release assays. Effector cells were
added at an E/T ratio of 10:1.
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sequence (Fig. 4B). The autologous viral sequence for
the epitope recognized by HCV58A1.4 differed from the
prototype (HCV-1) 1a sequence at one amino acid posi-
tion (ELAAKLVAL to ELAAKLVGL) in 10 of 10 transfor-
mants (Fig. 4C). For subject HCV58, an additional plasma
sample was obtained 50 months after the liver biopsy.
Analysis of the endogenous viral sequence at the
epitope recognized by clone HCV58A1.4 showed no in-
terval change (Fig. 4C).
Recognition of autologous viral sequence by the CTL
clones
We analyzed the ability of the autologous (genotype
2a) sequence to sensitize targets for lysis by the clones
HCV57.19 and HCV57.8. HCV57.8 was able to recognize
target cells loaded with the 1a epitope at peptide con-
centrations as low as 25 pM. However, the clone was
unable to lyse target cells loaded with the autologous
peptide sequence at any concentration tested (Fig. 5A).
HCV57.19 recognized the 2a epitope, although the clone
required substantially higher concentrations of peptide
to be loaded onto target cells to recognize the 2a se-
quence than the 1a sequence (Fig. 5B). HCV57.19 never
recognized target cells loaded with ,50 nM of the ge-
notype 2a peptide, whereas the 1a epitope was some-
times recognized at a peptide concentration of 50 pM.
Recognition of the two peptides by clone HCV57.19 al-
ways differed by 100- to 1000-fold.
We then examined the ability of the prototype and
autologous genotype 1a viral epitopes to render target
cells susceptible for lysis by the clone HCV58A1.4. The
clone was able to recognize and lyse target cells loaded
with $500 nM of the HCV-1 sequence (ELAAKLVAL) but
required 200-fold more of the autologous viral peptide to
lyse peptide-loaded targets (Fig. 5C).
DISCUSSION
In this report, we identified two intrahepatic CD81 CTL
clones specific for the HCV NS3 protein and one clone
specific for the NS2 protein from two chronically infected
individuals. The NS2-specific clone, HCV57.8, is re-
stricted by the HLA-B37 allele and recognizes an epitope
not previously described (amino acids 957–964; RD-
WAHNGL). HCV57.19 recognizes an epitope correspond-
ing to amino acids 1406–1415 within the NS3 region in
the context of HLA-A2.1. The peptide from genotype 1a,
TABLE 2
Mapping of the Epitope Recognized by the HLA-B8 Restricted HCV-Specific CTL Clone HCV58A1.4
Experiment Peptide
Lysis (%)
50 mM 5 mM 500 nM No peptide
1 1391–1410 LIFCHSKKKCDELAAKLVAL 55 50 21 21
1401–1420 DELAAKLVALGINAVAYYRG 58 34 5 21
1391–1402 LIFCHSKKKCDELA 12 26 26 21
1394–1407 CHSKKKCDELAAKL 215 216 216 21
1397–1410 KKKCDELAAKLVAL 62 54 3 21
2 1401–1410 DELAAKLVAL 47 34 12 22
1402–1410 ELAAKLVAL 50 44 34 22
1402–1409 ELAAKLVA 14 22 22 22
1403–1410 LAAKLVAL 1 1 1 22
Note. HCV NS3-derived peptides were loaded onto autologous B-LCLs and used as target cells in 6-h chromium release assays. Effector cells were
added at an E/T ratio of 10:1.
FIG. 4. Sequence of autologous CTL epitopes. Regions of the HCV
genome containing each CTL epitope were amplified from endogenous
viral RNA isolated from the plasma of each patient using RT-PCR. The
PCR fragments were cloned and sequence analysis was performed on
10 transformants for each epitope. Underlined amino acids are those
that differ from the prototype sequence. *One sequence contained a
single nucleotide deletion within the CTL epitope.
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KLVALGINAV, has been identified before as an epitope
recognized by HLA-A2.1-restricted CTL isolated from pe-
ripheral blood mononuclear cells (PBMCs) of HCV-
infected patients (Cerny et al., 1995; Rehermann et al.,
1996). HCV58A1.4 is restricted by HLA-B8 and recognizes
an epitope not previously described (amino acids 1402–
1410; ELAAKLVAL), which overlaps with the HLA-A2.1
epitope and with another HLA-B8-restricted epitope de-
scribed by Koziel et al. (1995) (HSKKKCDEL). This adds to
existing data demonstrating that the flavivirus nonstruc-
tural proteins are frequent targets for CTL (Cerny et al.,
1995; Diepolder et al., 1995; Koziel et al., 1995; Kurane et
al., 1991; Livingston et al., 1995; Mathew et al., 1996;
Missale et al., 1996; Rehermann et al., 1996). This is
potentially important for vaccine development because
the NS3 protein is among the more highly conserved
flaviviral proteins and many flavivirus NS3-specific CTL
have been crossreactive with closely related flaviviruses
(Kurane et al., 1991). Furthermore, recent studies have
shown that an efficient T cell response to the NS3 protein
may correlate with self-limited acute infection (Diepolder
et al., 1995; Missale et al., 1996).
Clone HCV57.19 recognized the prototype genotype 1a
sequence (KLVALGINAV) at very low peptide concentra-
tions, requiring as little as 50 pM of peptide to be loaded
onto target cells to render them susceptible for lysis.
However, when the clone was analyzed for its ability to
recognize and lyse target cells loaded with the autolo-
gous sequence (ALRGMGVNAV), 1000-fold higher con-
centrations of peptide were required. Clone HCV58A1.4
also inefficiently recognized the autologous peptide se-
quence, requiring $25 mM of peptide to be loaded onto
target cells for recognition. The NS2-specific clone
HCV57.8 was able to recognize as little as 25 pM of the
prototype 1a sequence RDWAHNGL loaded onto target
cells; however, it was unable to lyse targets loaded with
as much as 25 mM of the autologous peptide sequence.
Several groups of investigators have studied HCV-
specific responses in liver-infiltrating or peripheral blood
lymphocytes. Most of these studies were performed with
mixed CTL populations, however, and in some cases the
epitopes recognized by CTL were not defined (Battegay
et al., 1995; Cerny et al., 1995; Diepolder et al., 1995;
Koziel et al., 1995; Missale et al., 1996; Nelson et al.,
1997; Rehermann et al., 1996). Chang et al. (1997) ana-
lyzed the CTL response to prototype genotype 1a and
autologous viral sequences in 13 patients chronically
infected with HCV. In four of these patients, a CTL re-
sponse could be detected against the epitopes of the
HCV-1 (genotype 1a) prototype sequence, but there was
no response to the corresponding autologous viral se-
quence. Hiroishi et al. (1997) and Kaneko et al. (1997)
studied the recognition of autologous viral sequences at
an HLA-B44-restricted CTL epitope on the HCV C pro-
tein. They described one variant sequence that acted as
a partial agonist/antagonist to restimulation of CTL in
vitro (Kaneko et al., 1997).
The studies cited above analyzed HCV-specific CTL
lines derived from PBMCs after multiple rounds of stim-
ulation with synthetic peptides in vitro and focused on
specific epitopes presented by HLA-A2 or HLA-B44. The
correlation between HCV-specific CTL responses in the
liver and those measured from PBMCs in this manner
remains uncertain, however. The published data on in-
trahepatic HCV-specific CTL are more limited (Koziel et
al., 1992, 1993, 1995; Wong et al., 1998). These data
demonstrate that HCV-specific CTL are present in much
higher frequency in liver tissues and can be isolated
from these tissues without the selective pressure of
antigenic stimulation in vitro. Minutello et al. (1993) dem-
onstrated that the HCV-specific T cell population isolated
from liver tissues and PBMCs by antigenic stimulation
may not be identical.
FIG. 5. Concentration dependence of recognition of respective pro-
totype HCV genotype 1a peptide and autologous HCV peptides by
clone HCV57.8 (A), HCV57.19 (B), and HCV58A1.4 (C). Autologous B-
LCLs were loaded with various concentrations of either the prototype
1a (F) peptide or autologous (E) peptide and used as target cells in a
6-h chromium release assay. Effector cells were added at an E/T ratio
of 10:1. Underlined amino acids are those that differ from the prototype
sequence.
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Our results therefore expand on the observations of
others by demonstrating that liver-derived CTL that rec-
ognize the prototype HCV sequences may be markedly
less efficient at recognizing the autologous viral se-
quences. We do not know whether a response to the
autologous epitopes would have been detected at all in
bulk culture, but it is feasible that it would have been
undetected. We conclude, however, that the results of
CTL assays using target cells expressing prototype HCV
sequences must be interpreted with caution because
they may not accurately reflect the activity of these CTL
in vivo.
Several limitations of this study must be recognized.
Our study is limited in size, involving three CTL clones
from two subjects. Further studies will clearly be re-
quired to determine the generalizability of our observa-
tions. Three other HCV-specific CTL clones were iso-
lated from subject HCV57 but could not be maintained in
culture long enough to permit mapping of the epitopes
recognized and sequencing of the autologous viral
epitopes. However, our isolation of a limited number of
HCV-specific CTL clones from each subject is consistent
with the observations of others that at most one to five
HCV-specific CTL clones were isolated from each spec-
imen (Koziel et al., 1995; Wong et al., 1998).
Another potential confounding factor is that we iden-
tified HCV-specific CTL only after screening for recogni-
tion of the prototype HCV sequences. As a result, we
would not have identified HCV-specific CTL that recog-
nize the autologous viral sequence efficiently but are
unable to recognize the prototype viral sequences. A
definitive solution to this potential problem would require
that the full endogenous HCV genome(s) be cloned into
an expression system before analysis of the CTL re-
sponse. Although this concern does require cautious
interpretation of our data, we believe it only strengthens
our conclusion that interpretation of CTL recognition of
prototype HCV sequences can be misleading. Further-
more, this concern would apply in equal or greater mea-
sure to the data of other groups who focus on specific
peptide epitopes selected based on the binding affinity
of the prototype sequences for particular HLA alleles
(Chang et al., 1997).
We cannot determine whether the inefficient recogni-
tion of autologous viral sequences in the individuals we
studied is attributable to mutation of the endogenous
virus, evolution of the CTL response, or the T cell reper-
toire. For example, these CTL clones may reflect the
response to HCV sequences present earlier in infection
that have been eliminated or persist at low frequency.
The implications of inefficient CTL responses with regard
to the course of disease also are uncertain. If the intra-
hepatic HCV-specific CTL require high levels of antigen
expression before target cell recognition, the CTL might
be less efficient at suppressing viral replication. Alex-
ander-Miller et al. (1996) demonstrated that CTL clones
with lower avidity were less efficient at eliminating vac-
cinia virus infection in vivo. In this regard, the absence of
viral mutations in the CTL epitope in subject HCV58
during a 50-month period after isolation of the CTL might
not be surprising because the CTL response might not
be sufficiently strong to exert selective pressure on the
virus.
MATERIALS AND METHODS
Patients
Liver and blood specimens were obtained from pa-
tients with chronic HCV infection seen in the outpatient
clinics of the Liver, Biliary, and Pancreatic Center of the
University of Massachusetts Medical Center (UMMC).
PBMCs were separated from whole blood by Ficoll–
Hypaque density gradient centrifugation. Fragments of
liver tissue were obtained from biopsy specimens ob-
tained for clinical indications. All specimens were cryo-
preserved in RPMI 1640 medium supplemented with
L-glutamine, penicillin (100 U/ml), streptomycin (100 mg/
ml), 20% FCS, and 10% DMSO. Research protocols were
approved by the Institutional Review Board of UMMC.
Cloning of liver-infiltrating lymphocytes
Cryopreserved liver tissue was thawed, washed, re-
suspended in 1.5 ml of serum-free medium containing 2
mg/ml collagenase, and incubated for 2.5 h at 37°C with
periodic vortexing. The cells then were washed twice in
RPMI 1640 supplemented with L-glutamine (2 mM), pen-
icillin (100 U/ml), streptomycin (100 mg/ml), b-mercapto-
ethanol (50 mM), and 10% FCS (complete medium);
counted; and cultured as indicated below.
Lymphocytes initially grown in bulk culture were
seeded onto 24-well plates in complete medium with
either rhIL-2 (50 U/ml) alone or with PHA (1:500), g-irra-
diated allogeneic PBMCs (5 3 106 cells/well), and rhIL-2
(50 U/ml). After 2 weeks, all cultures were restimulated
with PHA, g-irradiated allogeneic PBMCs, and rhIL-2.
Lymphocytes that were cultured in limiting dilution
were seeded at 100, 25, or 5 cells/well in 96-well plates.
The cells were stimulated with PHA, g-irradiated alloge-
neic PBMCs (1 3 105 cells/well), and rhIL-2. Wells show-
ing growth were expanded into 48-well plates and then
tested for HCV-specific cytotoxicity. CTL lines and clones
were maintained by restimulation every 2 weeks with
g-irradiated allogeneic PBMCs, PHA, and rhIL-2.
Cell lines
Autologous B-LCLs were established from the sub-
jects’ PBMCs by infection with Epstein–Barr virus and
were maintained in RPMI 1640 supplemented with
L-glutamine, penicillin, streptomycin, and 20% FCS.
HmyCR1 cell lines were obtained from Dr. William
Biddison at the National Institutes of Health and were
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maintained in RPMI 1640 supplemented with L-glu-
tamine, penicillin, streptomycin, and 20% FCS.
Recombinant vaccinia viruses
The vaccinia virus recombinants used in this study
were kindly provided by Dr. Michael Houghton (Chiron
Corp.); vvC-NS2 expresses the portion of the HCV ge-
nome encoding amino acids 1–967, and vvE2-NS3 en-
codes amino acids 364–1619 (Choo et al., 1991; Koziel et
al., 1993, 1992). Both viruses were constructed using
sequences from the HCV-1 (genotype 1a) genome. The
vaccinia construct vv826–3011 was kindly provided by Dr.
Charles Rice (Washington University, St Louis).
Synthetic peptides
Peptides were synthesized in the UMMC Peptide Core
Facility using the Symphony automated peptide synthe-
sizer (Rainin Instruments, Woburn, Massachusetts). Ly-
ophilized peptides were reconstituted in DMSO at a
concentration of 10 mM and stored at 220°C.
Cytotoxicity assay using vaccinia-infected target cells
Autologous B-LCLs were infected with either HCV-
expressing recombinant vaccinia viruses or wild-type
vaccinia virus (vvcont) at an m.o.i. of 5 plaque-forming
units/cell at 37°C. After overnight incubation, the infected
B-LCLs were labeled with 250 mCi Na2
51CrO4 at 37°C for
1 h. The cells were washed three times in complete
medium and used as target cells (3 3 103/well) in a
chromium release assay. The expanded lymphocyte cul-
tures or cultured clones were used as effector cells,
which were always tested in triplicate. Supernatants
were harvested after 6 h of incubation at 37°C using the
Skatron supernatant collecting system (Skatron, Sterling,
Virginia).
Percent specific lysis was determined by the formula
100 3 [(experimental release-minimum release)/(maxi-
mum release 2 minimum release)]. Minimum release
was usually ,30% of the maximum release.
Cytotoxicity assay using peptide-sensitized target
cells
Uninfected B-LCLs were labeled with Na2
51CrO4 for
1 h at 37°C as above and placed into 96-well plates at
3 3 103 cells/well. Peptide and effectors were added
separately. Supernatants were harvested and specific
lysis was calculated as described above.
HLA typing
Class I HLA typing was performed on PBMCs or B-
LCLs by the tissue typing laboratories at UMMC (subject
HCV57) and George Washington University (subject
HCV58). The class I HLA types of the subjects in this
report were HCV57-A2 A3 B7 B37 Cw6 Cw7 and
HCV58-A2 A3 B7 B8 Cw7.
Phenotypic analysis of T cell lines
Cells were incubated with fluorescein isothiocyanate-
labeled monoclonal antibodies specific for CD3, CD4, or
CD8 (Becton-Dickinson, Mountain View, California),
washed, fixed with 2% paraformaldehyde, and analyzed
by flow cytometry at the central UMMC FACS facility.
Genotyping plasma HCV RNA
A second-generation method of genotyping HCV by
PCR with sense and antisense primers developed by
Okamoto et al. (1996) was used to determine the geno-
type of viral RNA in the subjects’ plasma. Briefly, HCV
RNA extracted from the plasma of each patient was
reverse-transcribed and amplified with universal primers
in a PCR that produced a 433-bp HCV core gene frag-
ment. This PCR product then was subjected to a second
set of five PCR, each containing sense and antisense
primers specific for one of five genotypes of HCV: 1a, 1b,
2a, 2b, and 3a. PCR products were analyzed on 3%
agarose gels.
Analysis of endogenous HCV sequences
To determine the autologous sequence of the epitope
recognized by the CTL clones, viral RNA was isolated
from 100 ml of plasma using Ultraspec RNA isolation
reagent (Biotecx, Houston, Texas) and reverse-tran-
scribed at 37°C using either an HCV-specific antisense
primer (primer 4896 for the HCV57 NS3 epitope and
primer 3426 for the HCV57 NS2 epitope) or random
primers (HCV58 NS3 epitope). Each cDNA was amplified
by PCR according to the conditions described below for
each epitope. PCR products were run on a 1.5% agarose
gel, and the fragments were isolated from a gel slice
using the Qiaquick gel extraction kit (Qiagen, Chats-
worth, California). The DNA was eluted with 50 ml of TE
buffer and ligated into the pCRII cloning vector (InVitro-
gen, Carlsbad, California). Transformants were selected
via blue/white selection and screened for presence of an
insert by restriction analysis. Ten transformants contain-
ing inserts were selected and were sequenced using the
ABI automated sequencer at the UMMC nucleic acid
facility.
Amplification of the NS3 region from HCV57 viral
cDNA. A 599-bp fragment within the NS3 region of the
HCV57 viral genome was generated by using the primers
4896 (59-4896: GCATCGTAGCACTCGCAGAGCACTA) and
4322 (59-4322: ACCACCATTCTCGCCATCGGAAACAG) for
35 PCR cycles (94°C for 30 s, 60°C for 60 s, and 72°C for
2 min) in a 50-ml reaction containing 5 ml of the cDNA
and 20 pmol of each primer.
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Amplification of the NS2 region from HCV57 viral
cDNA. A nested PCR was performed to generate a
206-bp fragment. Primers 3023 (59-3023: TGGCTCTTG-
GCGGTGCTT) and 3426 (59-3426: CAGTGATGGGGGC-
GAGAA) were added in a 50-ml reaction containing 1 ml
of cDNA and 20 pmol of each primer for 30 PCR cycles
(94°C for 1 min, 59°C for 2 min, and 72°C for 3 min). An
additional 30 cycles of PCR were performed on 1 ml of
product from the first reaction using primers 3091 (59-
3091: CAGGGCTCACGCTCTACT) and 3279 (59-3279:
TTTTCTCCATCGGACTGA) for 94°C for 1 min, 55°C for 2
min, and 72°C for 3 min.
Amplification of the NS3 region from HCV58 viral
cDNA. To generate the 247-bp fragment within NS3, a
nested PCR protocol described by Weiner et al. (1995)
was followed. PCR amplification of cDNA was performed
for 30 cycles (94°C for 30 s, 50°C for 1 min, and 72°C for
3 min) using primers 4376 (59-4376: GTCCGCCACCGC-
CACCCCTC) and 4797 (39-4797: CCAGTCCTGCCCCG-
ACGTTG). A nested PCR using primers 4503 (59-4503:
GGGAGACATCTCATCTTCTG) and 4777 (39-4777: CTG-
GGGGAGCGTGATTGTCTCAAT) was performed on 1 ml
of PCR product from the first reaction for 30 cycles (94°C
for 30 s, 48°C for 1 min, and 72°C for 3 min).
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